• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-氮杂胞苷在治疗伴有自身免疫表现的 HTLV-1 阳性骨髓增生异常综合征中的抗逆转录病毒活性。

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

机构信息

1st Department of Internal Medicine, Haematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens 11527, Greece.

出版信息

Virol J. 2012 Jan 3;9:1. doi: 10.1186/1743-422X-9-1.

DOI:10.1186/1743-422X-9-1
PMID:22214262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3305386/
Abstract

Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.

摘要

骨髓增生异常综合征(MDS)常伴有自身免疫现象。这些关联的潜在机制尚不确定,尽管 T 细胞激活似乎很重要。人类 T 淋巴细胞病毒(HTLV-1)已在骨髓增生异常综合征患者中检测到,主要在病毒流行的世界区域,并且 HTLV-1 与风湿表现的关联并不罕见。我们在此介绍一位 58 岁男性患者,他表现为血细胞减少、皮肤白细胞碎裂性血管炎和肾小球病,并被诊断为 MDS(难治性贫血伴原始细胞增多-RAEB 1)。该患者还通过 PCR 检测出 HTLV-1 阳性。经过 8 个 5-氮杂胞苷周期的治疗后,他达到了完全血液学缓解。治疗后,进行了第二次 HTLV-1 的 PCR 检测,结果为阴性。这是文献中首例 HTLV-1 阳性 MDS 伴严重自身免疫表现的病例,采用低甲基化因子 5-氮杂胞苷治疗,取得了细胞遗传学缓解,同时自身免疫表现也得到了缓解,以及 HTLV-1-PCR 阴性。HTLV-1-PCR 阴性可能是由于病毒的免疫清除,或 5-氮杂胞苷的潜在抗逆转录病毒作用。5-氮杂胞苷以其抗逆转录病毒作用而闻名,尽管没有证据表明其在体内对 HTLV-1 感染具有活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/3305386/f4821aca62d1/1743-422X-9-1-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/3305386/823f60fd3a80/1743-422X-9-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/3305386/f4821aca62d1/1743-422X-9-1-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/3305386/823f60fd3a80/1743-422X-9-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/3305386/f4821aca62d1/1743-422X-9-1-2.jpg

相似文献

1
Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.5-氮杂胞苷在治疗伴有自身免疫表现的 HTLV-1 阳性骨髓增生异常综合征中的抗逆转录病毒活性。
Virol J. 2012 Jan 3;9:1. doi: 10.1186/1743-422X-9-1.
2
Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.分子学确诊的阿扎胞苷治疗骨髓增生异常综合征病例的细胞遗传学缓解
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Dec 1;38(3):157-162. doi: 10.2478/prilozi-2018-0017.
3
Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review.骨髓增生异常综合征中自身免疫和炎症性疾病对 5-氮杂胞苷的反应:两例报告及文献复习。
Ann Palliat Med. 2021 Aug;10(8):9276-9280. doi: 10.21037/apm-21-1416.
4
[Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].[阿扎胞苷有效治疗真性红细胞增多症转化的骨髓增生异常综合征]
Rinsho Ketsueki. 2013 May;54(5):468-72.
5
Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population.中欧人群中人类T细胞白血病病毒与骨髓增生异常综合征的关联。
Cancer Res. 1997 Nov 1;57(21):4718-21.
6
High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia.在伴有过多原始细胞的难治性贫血(RAEB)、转化中的RAEB和急性早幼粒细胞白血病患者中,I型人类嗜T淋巴细胞病毒携带者的高患病率。
Leuk Lymphoma. 2008 Feb;49(2):315-21. doi: 10.1080/10428190701799019.
7
Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy.一名骨髓增生异常综合征患者的自身免疫性溶血性贫血:对5-氮杂胞苷治疗有反应。
J Oncol Pharm Pract. 2021 Oct;27(7):1775-1778. doi: 10.1177/1078155220987616. Epub 2021 Jan 14.
8
Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.骨髓增生异常综合征中 Dab2 基因启动子异常甲基化。
Eur J Haematol. 2012 Dec;89(6):469-77. doi: 10.1111/ejh.12014. Epub 2012 Oct 16.
9
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.阿扎胞苷指导下的治疗以预防骨髓增生异常综合征和急性髓系白血病患者血液学复发(RELAZA2):一项开放标签、多中心、2 期试验。
Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.
10
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.对于诱导化疗后完全缓解的高危骨髓增生异常综合征(MDS)或 MDS 后急性髓系白血病患者,用阿扎胞苷进行维持治疗。
Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20.

引用本文的文献

1
parazitCUB: An R package to streamline the process of investigating the adaptations of parasites' codon usage bias.parazitCUB:一个 R 包,用于简化调查寄生虫密码子使用偏好适应性的过程。
F1000Res. 2023 Nov 2;12:1431. doi: 10.12688/f1000research.143223.1. eCollection 2023.
2
Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis.阿扎胞苷和葡甲胺锑对利什曼原虫的抗利什曼原虫潜力:计算机预测和体外分析。
PLoS One. 2023 Sep 8;18(9):e0291321. doi: 10.1371/journal.pone.0291321. eCollection 2023.
3
Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19.

本文引用的文献

1
Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma.阿扎胞苷诱导 p16INK4a 去甲基化并抑制成人 T 细胞白血病/淋巴瘤的生长。
Int J Mol Med. 2011 Nov;28(5):835-9. doi: 10.3892/ijmm.2011.756. Epub 2011 Jul 22.
2
Exploiting drug repositioning for discovery of a novel HIV combination therapy.挖掘药物再利用以发现新型 HIV 联合疗法。
J Virol. 2010 Sep;84(18):9301-9. doi: 10.1128/JVI.01006-10. Epub 2010 Jul 7.
3
Association of human T lymphotropic virus type I with Sjogren syndrome.I型人类嗜T淋巴细胞病毒与干燥综合征的关联。
阿扎胞苷靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒RNA作为2019冠状病毒病(COVID-19)的一种潜在治疗方法。
Sci Bull (Beijing). 2022 May 30;67(10):1022-1025. doi: 10.1016/j.scib.2022.02.002. Epub 2022 Feb 12.
4
Drug repositioning by merging active subnetworks validated in cancer and COVID-19.通过合并癌症和 COVID-19 中验证的活性子网络进行药物重定位。
Sci Rep. 2021 Oct 6;11(1):19839. doi: 10.1038/s41598-021-99399-2.
5
The Roles of Host 5-Methylcytosine RNA Methyltransferases during Viral Infections.宿主 5-甲基胞嘧啶 RNA 甲基转移酶在病毒感染中的作用。
Int J Mol Sci. 2020 Oct 31;21(21):8176. doi: 10.3390/ijms21218176.
6
Selected nucleos(t)ide-based prescribed drugs and their multi-target activity.选定的核苷(酸)类处方药及其多靶点活性。
Eur J Pharmacol. 2019 Dec 15;865:172747. doi: 10.1016/j.ejphar.2019.172747. Epub 2019 Oct 18.
7
Brca1 Is Upregulated by 5-Aza-CdR and Promotes DNA Repair and Cell Survival, and Inhibits Neurite Outgrowth in Rat Retinal Neurons.Brca1 通过 5-Aza-CdR 上调,促进 DNA 修复和细胞存活,并抑制大鼠视网膜神经元的轴突生长。
Int J Mol Sci. 2018 Apr 17;19(4):1214. doi: 10.3390/ijms19041214.
8
Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.HIV感染控制良好的患者中的高危骨髓增生异常综合征:临床特征、治疗及转归
Case Rep Hematol. 2016;2016:8502641. doi: 10.1155/2016/8502641. Epub 2016 Jan 20.
9
Epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional suppression of Tregs.人类T细胞白血病病毒I型相关脊髓病/热带痉挛性截瘫(HAM/TSP)中FoxP3基因调控区(TSDR)的表观遗传修饰降低了调节性T细胞(Tregs)的功能抑制作用。
J Neuroimmune Pharmacol. 2014 Sep;9(4):522-32. doi: 10.1007/s11481-014-9547-z. Epub 2014 May 21.
Ann Rheum Dis. 2010 Nov;69(11):2056-7. doi: 10.1136/ard.2010.128736. Epub 2010 May 14.
4
Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.免疫抑制治疗骨髓增生异常综合征:细化适应证。
Curr Hematol Malig Rep. 2008 Jan;3(1):23-8. doi: 10.1007/s11899-008-0005-y.
5
Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma.多步异常 CpG 岛超甲基化与成人 T 细胞白血病/淋巴瘤的进展相关。
Am J Pathol. 2010 Jan;176(1):402-15. doi: 10.2353/ajpath.2010.090236. Epub 2009 Dec 17.
6
A clinical survey of uveitis in HTLV-1 endemic region.在 HTLV-1 流行地区的葡萄膜炎临床调查。
Ocul Immunol Inflamm. 2009 Sep-Oct;17(5):335-41. doi: 10.3109/09273940903137667.
7
5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.5-氮杂胞苷可诱导1型人类免疫缺陷病毒发生致死性诱变。
J Virol. 2009 Nov;83(22):11950-8. doi: 10.1128/JVI.01406-09. Epub 2009 Sep 2.
8
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).三氧化二砷、α干扰素和齐多夫定联合用药治疗新诊断成年慢性T细胞白血病/淋巴瘤(ATL)的疗效与安全性的2期研究
Blood. 2009 Jun 25;113(26):6528-32. doi: 10.1182/blood-2009-03-211821. Epub 2009 May 1.
9
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.骨髓增生异常综合征病理生理学中的自身免疫机制及其临床相关性。
Haematologica. 2009 Apr;94(4):449-51. doi: 10.3324/haematol.2009.006080.
10
Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS).骨髓增生异常综合征(MDS)中CD4+CD25+FOXP3+调节性T细胞的动力学、功能及骨髓归巢
Leukemia. 2009 Mar;23(3):510-8. doi: 10.1038/leu.2008.333. Epub 2008 Nov 20.